冠昊生物(300238) - 2025年4月30日投资者关系活动记录表

Financial Performance - The company achieved a revenue of 37,748.31 million yuan in 2024 [3] - The total profit amounted to 2,801.93 million yuan, with a net profit attributable to shareholders of 2,741.69 million yuan [3] Future Strategies - The company plans to optimize its product structure based on industry and market evaluations to ensure sustainable development [2] - Future profit growth will rely on core product technology upgrades, market share expansion, and alignment with national policy directions [4] Capital Raising and Stock Performance - The company is proceeding with a private placement at a price lower than the current stock price, adhering to regulatory policies [3] - The stock price is influenced by various market factors, and the company is committed to sustainable development and protecting investor interests [6] Industry Outlook - The biomedicine industry is undergoing significant changes, with a complex market environment in 2024 [4] - The company is focused on its main business while exploring new opportunities in line with national policies and industry trends [5] Project Updates - The clinical trial for the company's product for atopic dermatitis is actively ongoing [5] - The Zhongshan Tianhao Pharmaceutical Technology project was completed in 2024 and will gradually commence production [5]